Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)

计划入组 712 人 · 首次发布于 2017 年 3 月 23 日

STUDY OF PEMBROLIZUMAB (MK-3475) COMPARED TO PLATINUM-BASED CHEMOTHERAPIES IN PARTICIPANTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (MK-3475-042/KEYNOTE-042)

计划入组 25 人

Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024)

计划入组 305 人 · 首次发布于 2014 年 5 月 20 日

Platinum

Pt

aerosolized platinum

Platinum anticancer agent(Zhejiang Hisun Pharmaceutical)

Platinum Capital Ltd

Platinum Trident Enterprise LLC

United States

EVIDENCE-BASED PRACTICE INSTITUTE, INC.

United States

China CDE Grants Breakthrough Therapy Designation to Sunvozertinib for First-Line EGFR Exon20ins NSCLC

Ascentage Pharma's APG-2449 Advances to Phase III Trials for NSCLC Treatment

CHMP Recommends Mirvetuximab Soravtansine (ELAHERE®) for Platinum-Resistant Ovarian Cancer